Form 4: Opus Genetics CEO Receives Stock and Option Grants
SEC Form 4 Filing
CEO of Opus Genetics, George Magrath, receives a grant of restricted stock units and an employee stock option.
Summary
- George Magrath, the CEO of Opus Genetics, received 330,697 shares of common stock and an option to purchase 330,697 shares on March 13, 2025.
- The stock was granted at $0 per share.
- The option has an exercise price of $0.93 per share and expires on March 12, 2035.
- The restricted stock units vest in four equal installments annually starting March 13, 2026.
- The options vest 25% on March 13, 2026, and the remaining shares vest quarterly over the following 12 quarters.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive event.
Positives
- The grant of stock and options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock and option grants are a common form of executive compensation in the biotechnology industry, aligning management incentives with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages in the biotech industry typically include a mix of salary, bonus, stock options, and restricted stock units.
- The size and vesting schedule of these grants are often benchmarked against peer companies of similar size and stage of development.
- For example, companies like CRISPR Therapeutics and Editas Medicine also use stock options and restricted stock units as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see it as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/13/2025 | Date of transaction: Grant of restricted stock units and employee stock option. |
| 03/13/2026 | First vesting date for 25% of the employee stock option. |
| 03/12/2035 | Expiration date of the employee stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.